Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

NCT03446573 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

743

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: DTG + 3TC
DRUG: TAF based regimen (TBR)

Sponsor

ViiV Healthcare

Collaborators

[object Object]